Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock Has Average Price Target of $11.50

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have earned an average recommendation of “Hold” from the seven ratings firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $11.50.

A number of research firms have issued reports on KPTI. Weiss Ratings lowered shares of Karyopharm Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 24th. Rodman & Renshaw cut shares of Karyopharm Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, November 2nd. Wall Street Zen downgraded shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Robert W. Baird lowered shares of Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and set a $3.00 price objective for the company. in a research report on Friday, July 31st. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $16.00 price objective on shares of Karyopharm Therapeutics in a research note on Tuesday, July 21st.

Karyopharm Therapeutics Price Performance

KPTI traded down $0.00 during midday trading on Friday, reaching $0.02. 121,835,945 shares of the company’s stock were exchanged, compared to its average volume of 24,322,726. Karyopharm Therapeutics has a 1-year low of $0.02 and a 1-year high of $10.99. The stock has a market capitalization of $362,880.00, a PE ratio of -0.00 and a beta of 1.16. The business’s 50-day moving average price is $0.85 and its 200 day moving average price is $5.69.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Thursday, August 13th. The company reported ($2.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.37) by ($0.95). The business had revenue of $33.43 million during the quarter, compared to analysts’ expectations of $32.19 million. As a group, analysts expect that Karyopharm Therapeutics will post -4.05 EPS for the current fiscal year.

Institutional Trading of Karyopharm Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Commodore Capital LP purchased a new stake in Karyopharm Therapeutics in the first quarter valued at approximately $10,862,000. Avidity Partners Management LP grew its stake in shares of Karyopharm Therapeutics by 244.6% during the 1st quarter. Avidity Partners Management LP now owns 463,741 shares of the company’s stock valued at $2,583,000 after buying an additional 329,175 shares during the period. Context Capital Management LLC acquired a new stake in shares of Karyopharm Therapeutics during the 3rd quarter worth $322,000. Renaissance Technologies LLC increased its holdings in shares of Karyopharm Therapeutics by 75.9% during the 1st quarter. Renaissance Technologies LLC now owns 105,414 shares of the company’s stock worth $587,000 after buying an additional 45,500 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth $623,000. 66.44% of the stock is owned by institutional investors and hedge funds.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics is a biopharmaceutical company focused on developing treatments for cancer. Founded in 2008 and headquartered in Newton, Massachusetts, the company’s research centers on blocking nuclear export, a process that can help cancer cells survive and grow. Its lead product is selinexor, marketed in the United States as Xpovio. The oral therapy is approved for certain adults with multiple myeloma, including use in combination with other medicines. Karyopharm is also developing selinexor and other drug candidates for additional cancers.